Nephritis: Clinical Trials

351 completed, 198 recruiting, 141 unknown, 82 terminated. 275 Phase 2, 162 Phase 3, 126 Phase 1, 116 Not applicable, 90 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	275	Completed 106, Recruiting 57, Terminated 38, Unknown 27, Not yet recruiting 22, Active not recruiting 12, Withdrawn 11, Enrolling by invitation 2
Phase 3	162	Completed 57, Recruiting 27, Terminated 25, Unknown 20, Active not recruiting 15, Withdrawn 9, Not yet recruiting 7, Enrolling by invitation 2
Phase 1	126	Completed 48, Recruiting 33, Terminated 11, Active not recruiting 9, Withdrawn 9, Not yet recruiting 7, Unknown 6, Enrolling by invitation 3
Not applicable	116	Completed 50, Unknown 25, Recruiting 21, Not yet recruiting 9, Withdrawn 4, Terminated 3, Active not recruiting 2, Enrolling by invitation 1, Suspended 1
Phase 4	90	Completed 36, Unknown 22, Recruiting 15, Terminated 6, Withdrawn 5, Not yet recruiting 4, Active not recruiting 2
Early Phase 1	24	Recruiting 9, Not yet recruiting 6, Completed 3, Unknown 3, Enrolling by invitation 2, Withdrawn 1

Follow Nephritis: new trials by email Literature Review of Nephritis trials Research Report on Nephritis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) NM8074 - IgA Nephropathy	Phase 2	Not yet recruiting	NovelMed Therapeutics	10	2028-02-01	2026-04-13
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus	Phase 1	Withdrawn	Caribou Biosciences, Inc.		2027-12-01	2025-09-19
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy	Early Phase 1	Not yet recruiting	Grit Biotechnology	30	2027-08-01	2026-09-11
A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease Sibeprenlimab - Primary Membranous Nephropathy, Minimal Change Disease	Phase 2	Not yet recruiting	Otsuka Pharmaceutical Development & Commercialization, Inc.	20	2026-12-15	2026-10-06
Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions Obinutuzumab Beta - Primary IgA Nephropathy	Phase 4	Not yet recruiting	Ruijin Hospital	20	2026-12-10	2026-10-22
A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN)	Phase 3	Not yet recruiting	Novartis Pharmaceuticals	340	2026-12-01	2026-09-30
A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab - Immunoglobulin A Nephropathy	Phase 2	Not yet recruiting	Biogen	25	2026-11-16	2026-10-22
Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria Electronic Health Record alert - Referral and Consultation, Glomerulonephritis	Not applicable	Not yet recruiting	Geisinger Clinic	1200	2026-11-01	2026-05-12
Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy Forxiga - Glomerulonephritis	Phase 2	Not yet recruiting	Centre Hospitalier Universitaire de Nice	20	2026-11-01	2026-06-22
Single-cell RNA Sequencing (scRNA-seq) to Investigate the Mechanisms Underlying the Induction of Regulatory T Cells in Patients With Extramembranous Glomerulonephritis Treated With Rituximab Peripheral blood immune-cell profiling by single-cell RNA sequencing and in vitro pathway modulation assays - Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced	Not applicable	Not yet recruiting	Centre Hospitalier Universitaire de Nice	12	2026-10-31	2026-09-10
Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN) Sibeprenlimab, Standard of care - IgA Nephropathy	Phase 3	Not yet recruiting	Otsuka Pharmaceutical Development & Commercialization, Inc.	24	2026-10-30	2026-10-15
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease	Phase 1	Not yet recruiting	Bristol-Myers Squibb	60	2026-10-30	2026-10-14
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease	Phase 2	Recruiting	National Human Genome Research Institute (NHGRI)	30	2026-10-29	2026-10-26
A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe Povetacicept, Sibeprenlimab - Immunoglobulin A Nephropathy	Phase 3	Not yet recruiting	Vertex Pharmaceuticals Incorporated	40	2026-10-23	2026-10-22
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) Antiphospholipid (aPL)-Positive, Rheumatic Arthritis		Not yet recruiting	Axiom Bioregistry	5000	2026-10-18	2026-10-23
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN ARGX-121, Placebo - Immunoglobulin A Nephropathy (IgAN)	Phase 2	Not yet recruiting	argenx	120	2026-10-15	2026-10-16
IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy IBI3034, Placebo, Telitacicept - IgA Nephropathy (IgAN)	Phase 1	Not yet recruiting	Innovent Biologics (Suzhou) Co. Ltd.	100	2026-10-15	2026-10-21
Lupus Nephritis Care Pathway Lupus Nephritis (LN) Care Pathway - Lupus Nephritis (LN)	Not applicable	Recruiting	Duke University	25	2026-10-14	2026-10-19
Mediators of Loin Pain in IgA Nephropathy IgA Nephropathy (IgAN)		Enrolling by invitation	University of Leicester	40	2026-10-13	2026-10-20
Serum MPO-DNA Complexes as a Biomarker of Disease Activity in Systemic Lupus Erythematosus Systemic Lupus Erythematosus, Lupus Nephritis		Not yet recruiting	Assiut University	90	2026-10-01	2026-09-08

Showing 20 of 939. Sign in to see all of them.

Narrower conditions

Lupus Nephritis (331)  ·  Glomerulonephritis, IGA (268)  ·  Lupus Erythematosus, Systemic (131)  ·  Glomerulonephritis, Membranous (114)  ·  Glomerulonephritis (101)  ·  Glomerulosclerosis, Focal Segmental (101)  ·  Proteinuria (91)  ·  Kidney Diseases (74)  ·  Nephrotic Syndrome (53)  ·  Pyelonephritis (50)  ·  Nephrosis, Lipoid (48)  ·  Renal Insufficiency, Chronic (46)  ·  Autoimmune Diseases (44)  ·  Nephritis, Hereditary (38)

Broader conditions

Female Urogenital Diseases (938)  ·  Female Urogenital Diseases and Pregnancy Complications (938)  ·  Male Urogenital Diseases (938)  ·  Urogenital Diseases (934)  ·  Urologic Diseases (921)  ·  Kidney Diseases (865)  ·  Glomerulonephritis (736)  ·  Immune System Diseases (729)  ·  Autoimmune Diseases (661)  ·  Skin and Connective Tissue Diseases (399)  ·  Connective Tissue Diseases (382)  ·  Lupus Erythematosus, Systemic (212)  ·  Pathological Conditions, Signs and Symptoms (183)  ·  Pathologic Processes (115)

Interventions

Mycophenolic Acid (64)  ·  Cyclophosphamide (59)  ·  Prednisone (43)  ·  Rituximab (43)  ·  Tacrolimus (33)  ·  Prednisolone (27)  ·  Adrenal Cortex Hormones (21)  ·  Methylprednisolone (17)  ·  fludarabine (17)  ·  Azathioprine (15)  ·  dapagliflozin (12)  ·  voclosporin (12)  ·  Blood Specimen Collection (11)  ·  Cyclosporine (11)  ·  Glucocorticoids (11)

Sponsors

Novartis Pharmaceuticals (35)  ·  Assiut University (26)  ·  Assistance Publique - Hôpitaux de Paris (18)  ·  Nanjing University School of Medicine (17)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (15)  ·  Sun Yat-sen University (13)  ·  Mario Negri Institute for Pharmacological Research (12)  ·  Guangdong Provincial People's Hospital (11)  ·  Mayo Clinic (10)  ·  Aurinia Pharmaceuticals Inc. (9)  ·  Peking University First Hospital (9)  ·  Alexion Pharmaceuticals, Inc. (8)  ·  Amgen (8)  ·  Biogen (8)  ·  Centre Hospitalier Universitaire de Nice (8)

Countries

United States (308)  ·  China (267)  ·  France (117)  ·  Spain (98)  ·  United Kingdom (94)  ·  Germany (91)  ·  Italy (86)  ·  South Korea (77)  ·  Australia (76)  ·  Canada (68)  ·  Taiwan (58)  ·  Brazil (54)  ·  Argentina (53)  ·  Czechia (50)  ·  Japan (50)

Top investigators

Radko Komers, MD, PhD (5)  ·  Fernando C. Fervenza, M.D., Ph.D. (4)  ·  Howard Trachtman, MD (4)  ·  Jeffrey B Kopp, M.D. (4)  ·  Yasar Caliskan, MD (4)  ·  Zhihong Liu, Master (4)  ·  Cheuk-Chun Szeto, MD (3)

Results publications

PMID 38299639, PMID 34778952, PMID 35224732, PMID 38724717, PMID 37528520, PMID 38864363, PMID 40465397, PMID 26032537, PMID 40337980, PMID 40938675, PMID 26630142, PMID 37772889, PMID 28763548, PMID 33159213, PMID 33693991, PMID 35230699, PMID 37254256, PMID 39513526, PMID 39899371, PMID 10093981, PMID 18930568, PMID 19670912, PMID 20211892, PMID 21303745, PMID 22087680, PMID 28341274, PMID 29450636, PMID 31340979, PMID 33687069, PMID 35675911, PMID 36423588, PMID 36853224, PMID 37068952, PMID 37947276, PMID 38334499, PMID 39331470, PMID 39455063, PMID 39673415, PMID 40444214, PMID 40482854, PMID 41092316, PMID 41442197, PMID 42133432, PMID 42175562, PMID 42275148, PMID 42384439, PMID 10676716, PMID 10737279, PMID 11328918, PMID 11511139

NIH funding

2023 (13), 2025 (8), 2018 (7), 2019 (7), 2016 (5), 2017 (5), 2014 (4), 2015 (4), 2009 (2), R01DK131091 (2), R01DK141114 (2), U54DK083912 (2), 2005 (1), 2008 (1), 5RC2DK122397 (1)